// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Assessing the Role of ATF6α in the Alternative Activation of Macrophages in the Progression of Fibrotic Lung Diseases

O. Mekhael - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

Bleomycin

Induced Lung Fibrosis by Reducing Fibrosis, Inflammation, and ER Stress

M. Leduc - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Bleomycin

15 Signaling and the Pathogenesis of Pulmonary Arterial Hypertension

L. R. Hilton - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

IL-15

Coding RNA H19 in Coronary Artery Remodeling in PAH Patients with Right Ventricular Failure

V. Nadeau - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Right ventricular failure

N/A

Predictors of Return Acute Asthma Visits Among Patients Receiving Guideline Recommended Discharge Management in the Emergency Department

D. Radhakrishnan - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Epidemiology of Surgical Amputation After Sepsis

K. Reitz - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sepsis

N/A

5D) in Fibrotic Interstitial Lung Disease

A. Tsai - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

Physiological Response to Exercise and Vital Prognosis in Patients with Combined Pulmonary Fibrosis and Emphysema: Comparison to Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

C. Boily-Daoust - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Predictors of Mortality on Cardiopulmonary Exercise Testing in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE)

C. Boily-Daoust - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Trends in COPD Prevalence, Incidence and Health Services Use in Younger Adults

A. S. Gershon - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Dependent Asthma Is Associated with Airway Autoimmune Responses

M. Mukherjee - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Prednisone

The Respiratory Quotient During Maximal Incremental Exercise: A Graphical Analysis

G. L. Jones - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Oxygen Desaturation in Six Minute Walk Test Compared to Cardiopulmonary Exercise Testing in Interstitial Lung Disease: A Pilot Study

R. Yang - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Interstitial lung disease

N/A

Utility of Computed Tomography Body Composition Measures in Chronic Lung Disease: Systematic Review

D. Rozenberg - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

and Microvascular Endothelial Cells Drives Small Vessel Muscularization in Pulmonary Hypertension

N. Yaoita - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Respiratory Research Prioritization for Alberta

H. Sharpe - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The Social Determinants of Health. A Deeper Dive: Health Disparities in the Nation's Capital

S. Pakhale - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Centered Outcome for Perioperative Medicine

A. Jerath - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methadone hydrochloride

Tranexamic Acid Pharmacokinetics and Dosing in Prolonged Cardiac Surgery

A. Jerath - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Tranexamic acid

Evaluating Peripheral Blood Eosinophilia and Health Outcomes in Hospitalized Cystic Fibrosis Patients with Pulmonary Exacerbations

A. Siedlecki - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

N/A

Copyright © 2026. QuantiNova All rights reserved